Description
Bone Biopsy Market Forecast till 2030
Market Overview
The bone biopsy market is projected to register a CAGR of 5.25% during the gauge time frame. Bone biopsy utilizes a needle and imaging direction to wipe out a little example of bone for assessment under a magnifying lens. Bone biopsies might be utilized to approve the conclusion of a bone problem, inspect an irregularity, lay out the reason for torment or disease, or separate bone growths from different circumstances. Developing interest in insignificantly obtrusive methodology is fuelling the development of the worldwide bone biopsy market. An insignificantly obtrusive methodology is the utilization of various procedures to work with less harm to the patient’s body. It has different advantages, for example, less employable and post-usable significant difficulties, less post-usable torment, abbreviated clinic stays, and quicker recuperation times.
The increase in the worldwide bone biopsy market is driven by the elements like the rising commonness of bone malignant growths and expanding acknowledgment of bone marrow biopsy for finding and the d treatment of lymphoma and leukemia illness. What’s more, further developing medical services foundations across arising nations sets out to reward freedom for the market. Notwithstanding, severe administrative approaches are probably going to limit market development.
Market Segmentation
Based on Type, the global Bone Biopsy Market is bifurcated into Needle Biopsy and Open Biopsy. MRI-Guided and CT-Guided products make up the market’s GUIDED category. For the identification of live tumors, lesions that cannot be seen by CT, and bone marrow lesions, a biopsy performed under MRI guidance is very helpful (after chemotherapy or radiation).
The End User segment is made up of hospitals and Clinics, Surgical Centres, and Others. Bone biopsy proceeds as a short-term technique in the clinic that typically takes under an hour and clinics are one of the primary contact focus and the most trustable choice for patients. The developing frequency and predominance of malignant growth, rising interest in negligibly obtrusive strategies, and enormous geriatric patient populace are driving the interest in the bone biopsy.
Regional Analysis
In North America, the bone biopsy market is credited to the rising predominance of bone problems like bone disease, osteoporosis osteomyelitis, and others. Additionally, the presence of good repayment approaches, advanced medical services foundation, and quick reception of cutting-edge clinical innovations in the region drive the regional market development during the gauge time frame.
Asia-Pacific is expected to enlist the most noteworthy development rate over the estimated period. This is because of the elements like further developing medical services framework, government drives, and the rising patient populace experiencing bone malignant growth, bone Contamination, osteoporosis, constant kidney infection, and other bone problems. For example, as indicated by the Global Osteoporosis Establishment, by
Major Players
The Key companies operating in a global Bone Biopsy Market are Argon Medical (US), Braun Melsungen (Germany), Becton, Dickinson, and Company (US), Cardinal Health, Inc. (US), Mermaid Medical A / S (Denmark), Kimal PLC (UK), Stryker (US), Cook Group Incorporated (US), Remington Medical (Denmark), and Merit Medical Systems Inc. (US).
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF BONE CANCER
4.2.2 GROWING DEMAND FOR MINIMALLY INVASIVE PROCEDURES
4.2.3 INCREASING ACCEPTANCE OF BONE MARROW BIOPSY FOR DIAGNOSIS AND TREATMENT OF LYMPHOMA AND LEUKEMIA DISEASE
4.3 RESTRAINTS
4.4 OPPORTUNITIES
4.4.1 IMPROVING HEALTHCARE INFRASTRUCTURE ACROSS EMERGING COUNTRIES
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D AND DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES REVIEW
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF BUYERS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19
5.3.1 IMPACT ON DEMAND
5.3.2 IMPACT ON SUPPLY CHAIN
6 GLOBAL BONE BIOPSY MARKET, BY TYPE
6.1 OVERVIEW
6.2 NEEDLE BIOPSY
6.3 OPEN BIOPSY
7 GLOBAL BONE BIOPSY MARKET, BY GUIDED
7.1 OVERVIEW
7.2 MRI-GUIDED
7.3 CT-GUIDED
8 GLOBAL BONE BIOPSY MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS AND CLINICS
8.3 SURGICAL CENTERS
8.4 OTHERS
9 GLOBAL BONE BIOPSY MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 UK
9.3.3 FRANCE
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 AUSTRALIA
9.4.5 SOUTH KOREA
9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST
9.5.2 AFRICA
9.5.3 LATIN AMERICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL BONE BIOPSY MARKET
10.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL BONE BIOPSY MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
10.6.2 PARTNERSHIP/COLLABORATION
10.7 MAJOR PLAYERS FINANCIAL MATRIX
10.7.1 SALES 2021
10.7.2 R&D EXPENDITURE (USD MILLION), 2021
11.1 ARGON MEDICAL
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 B. BRAUN MELSUNGEN AG
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 BECTON, DICKINSON, AND COMPANY
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 CARDINAL HEALTH
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGIES
11.5 MERMAID MEDICAL GROUP
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIES
11.6 KIMAL PLC
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIES
11.7 STRYKER
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 COOK MEDICAL
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS/S OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 REMINGTON MEDICAL
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 MERIT MEDICAL SYSTEMS
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 SWOT ANALYSIS
11.10.6 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS
Reviews
There are no reviews yet.